Pharmacology of personality disorders

Psychiatric Times

Volumn 23, Issue 8, 2006, Pages

  Triebwasser, Joseph ^a,b   Siever, Larry J ^a,c,d  

^a Mount Sinai School of Medicine ^*  (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Special Evaluation Program for Mood and Personality Disorders

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845733690     PISSN: 08932905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (60)

1. Binks CA, Fenton M, McCarthy L, et al. Pharmacological interventions for people with borderline personality disorder. Cochrane Database Syst Rev. 2006;CD005653.
2. Paris J. Recentadvances in the treatment of borderline personality disorder. Can J Psychiatry. 2005;50:435-441.
3. Goodman M, New A, Siever L. Trauma, genes, and the neurobiology of personality disorders. Ann N Y Acad Sci. 2004;1032:104-116.
4. Siever LJ. Endophenotypes in the personality disorders. Dialogues Clin Neurosci. 2005;7:139-151.
5. Siever LJ, Davis KL. A psychobiological perspective on the personality disorders. Am J Psychiatry. 1991;148:1647-1658.
6. Heim C, Nemeroff CB. Neurobiology of early life stress: clinical studies. Semin Clin Neuropsychiatry. 2002;7:147-159.
7. Torgersen S, Lygren S, Oien PA, et al. A twin study of personality disorders. Compr Psychiatry. 2000;41:416-425.
8. Teicher MH, Andersen SL, Polcari A, et al. The neurobiological consequences of early stress and childhood maltreatment. Neurosci Biobehav Rev. 2003;27:33-44.
9. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with borderline personality disorder. Am J Psychiatry. 2001;158(suppl):1-52.
10. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119.
11. Soloff PH, George A, Nathan S, et al. Amitripryline versus haloperidol in borderlines: final outcomes and predictors of response. J Clin Psychopharmacol. 1989;9:238-246.
12. Traskman L, Asberg WI, Bertilsson L, Sjostrand L Monoamine metabolites in CSF and suicidal behavior. Arch Gen Psychiatry. 1981;38:631-636.
13. Coccaro EF, Siever LJ, Klar HM, et al. Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989; 46:587-599.
14. Salzman C, Wolfson AN, Schatzberg A, et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23-29.
15. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry. 1997;54:1081-1088.
16. Simpson EB, Yen S, Costello E, et al. Combined dialectical behaviortherapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:379-385.
17. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry. 2004;65:903-907.
18. Verkes RJ, Van der Mast RC, Hengeveld MW, et al. Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry. 1998;155:543-547.
19. Ekselius L, Von Knorring L. Changes in personality traits during treatment with sertraline or citalopram. Br J Psychiatry. 1999;174:444-448.
20. Rinne T, van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial forfemale patients with borderline personality disorder. Am J Psychiatry. 2002;159:2048-2054.
21. Minzenberg MJ, Grossman R, New AS, et al. Blunted hormone responses to ipsapirone are associated with trait impulsivity in personality disorder patients. Neuropsychopharmacology. 2006;31:197-203.
22. Siever LJ, Buchsbaum MS, New AS, et al. d,l-fenfluramine response in impulsive personality disorderassessed with [18F]fluorodeoxyglucose positron emission tomography. Neuropsychopharmacology. 1999;20:413-423.
23. New AS, Buchsbaum MS, Hazlett EA, et al. Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl). 2004;176:451-458.
24. Cornelius JR, Soloff PH, Perel JWI, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843-1848.
25. Soloff PH, Cornelius J, George A, et al. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry. 1993;50:377-385.
26. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behavior. J Affect Disord. 1982;4:291-298.
27. Battaglia J, Wolff TK, Wagner-Johnson DS, et al. Structured diagnostic assessment and depot fluphenazine treatment of multiple suicide attempters in the emergency department, Int Clin Psychopharmacol. 1999;14:361-372.
28. Zanarini MC, Frankenburg FR. Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry. 2001;62:849-854.
29. Bogenschutz MP, George Nurnberg H. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry. 2004;65:104-109.
30. Soler J, Pascual JC, Campins J, et al. Double-blind, placebo-controlled study of dialectical behaviortherapy plus olanzapinefor borderline personality disorder. Am J Psychiatry. 2005;162:1221-1224.
31. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833-838.
32. Friedel RO. Dopamine dysfunction in borderline personality disorder: a hypothesis. Neuropsychopharmacology. 2004;29:1029-1039.
33. de la Fuente JM, Lotstra F. A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol. 1994;4:479-486.
34. Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology. 2003;28:1186-1197.
35. Hollander E, Swann AC, Coccaro EF, et al. Impact of trait impulsivity and state aggression on divalproexversus placebo response in borderline personality disorder. Am J Psychiatry. 2005;162:621-624.
36. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar Il disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2002;63:442-446.
37. Nickel MK, Nickel C, Mitterlehner FO, et al. Topiramate treatment of aggression in female borderline personality disorder patients: a double-blind, placebo-controlled study. J Clin Psychiatry. 2004;65:1515-1519.
38. Nickel MK, Nickel C, Kaplan P, et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry. 2005;57:495-499.
39. Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19:287-291.
40. Loew TH, Nickel MK, Muehlbacher M, et al. Topiramate treatment for women with borderline personality disorder: a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2006;26:61-66.
41. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry. 2003;160:167-169.
42. Philipsen A, Richter H, Schmahl C, et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry. 2004;65:1414-1419.
43. Philipsen A, Schmahl C, Lieb K. Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry. 2004;37:196-199.
44. Russ MJ, Roth SD, Lerman A, et al. Pain perception in self-injurious patients with borderline personality disorder. Biol Psychiatry. 1992;32:501-511.
45. Schmahl C, Greffrath W, Baumgartner U, et al. Differential nociceptive deficits in patients with borderline personality disorder and self-injurious behavior: laser-evoked potentials, spatial discrimination of noxious stimuli, and pain ratings. Pain. 2004;110:470-479.
46. Kemperman I, Russ MJ, Shearin E. Self-injurious behavior and mood regulation in borderline patients. J Personal Disord. 1997;11:146-157.
47. Schmahl C. Neurobiology of BPD: an update. Presented at: Annual Meeting of the American Psychiatric Association; 2005; Atlanta.
48. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628-634.
49. Sheard MH. Effect of lithium on human aggression. Nature. 1971;230:113-114.
50. Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976;133:1409-1413.
51. Barratt ES, Kent TA, Bryant SG, Felthous AR. A controlled trial of phenytoin in impulsive aggression. J Clin Psychopharmacol. 1991;11:388-389.
52. Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol. 1997;17:341-349.
53. Ralevski E, Sanislow CA, Grilo CM, et al. Avoidant personality disorder and social phobia: distinct enough to be separate disorders? Acta Psychiatr Scand. 2005;112:208-214.
54. Fahlen T. Personality traits in social phobia, II: changes during drug treatment. J Clin Psychiatry. 1995;56:569-573.
55. Sansone RA, Rytwinski D, Gaither GA. Borderline personality and psychotropic medication prescription in an outpatient psychiatry clinic. Compr Psychiatry. 2003;44:454-458.
56. Heinze M, Andreae D, Grohmann R. Pharmacotherapy of personality disorders in German speaking countries: state and changes in the last decade. Pharmacopsychiatry. 2005;38:201-205.
57. Makela EH, Moeller KE, Fullen JE, Gunel E. Medication utilization patterns and methods of suicidality in borderline personality disorder. Ann Pharmacother. 2006;40:49-52.
58. Becker DF, Grilo CM, Edell WS, McGlashan TH. Comorbidityof borderline personality disorder with other personality disorders in hospitalized adolescents and adults. Am J Psychiatry. 2000;157:2011-2016.
59. Koenigsberg HW, Reynolds D, Goodman M, et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry. 2003;64:628-634.
60. Nickel MK, Muehlbacher M. Nickel C. et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006;163:833-838.